Medicines

Fulltext search

For help on how to get the results you want, see our search tips.

Search results

Categories

Human Remove Human filter Veterinary (8) Apply Veterinary filter

Medicine name

Active substance / international non-proprietary name (INN) / common name

Medicine

European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Paediatric investigation plans Remove Paediatric investigation plans filter Summaries of opinion (9) Apply Summaries of opinion filter Withdrawn applications (46) Apply Withdrawn applications filter Orphan designations (236) Apply Orphan designations filter Referrals (4) Apply Referrals filter Direct healthcare professional communication (20) Apply Direct healthcare professional communication filter

Product number

Patient safety

Yes (6) Apply Yes filter

Authorisation status

Authorised (173) Apply Authorised filter Refused (15) Apply Refused filter Withdrawn (7) Apply Withdrawn filter

ATC code

Marketing authorisation date

From:

To:

Marketing authorisation holder

Pharmacotherapeutic group

Date of opinion

From:

To:

PIP decision type

P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) (9) Apply P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) filter PM: decision on the application for modification of an agreed PIP (81) Apply PM: decision on the application for modification of an agreed PIP filter W: decision granting a waiver in all age groups for all conditions or indications (21) Apply W: decision granting a waiver in all age groups for all conditions or indications filter

PIP condition / indication

Pharmaceutical form(s)

Route(s) of administration

Decision date

From:

To:

PIP compliance check

Yes (21) Apply Yes filter

Compliance procedure number

Medicine type

Accelerated assessment Remove Accelerated assessment filter Conditional approval Remove Conditional approval filter Orphan medicine Remove Orphan medicine filter Additional monitoring (554) Apply Additional monitoring filter Biosimilar (88) Apply Biosimilar filter Exceptional circumstances (50) Apply Exceptional circumstances filter Generic (280) Apply Generic filter

Related medicine

Therapeutic area

Last updated

From:

To:

This week This month Last week Last month

First published

From:

To:

307 results

Remove all filtersRemove all filters

Medicine type Accelerated assessment Remove Accelerated assessment filter Conditional approval Remove Conditional approval filter Orphan medicine Remove Orphan medicine filter

Medicine European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Paediatric investigation plans Remove Paediatric investigation plans filter

Categories Human Remove Human filter

Sort by

List item

Human medicine European public assessment report (EPAR): Adcetris

Brentuximab vedotin, Lymphoma, Non-Hodgkin; Hodgkin Disease
Date of authorisation: 25/10/2012, , , Revision: 33, Authorised, Last updated: 21/06/2022
List item

Human medicine European public assessment report (EPAR): Maviret

glecaprevir, pibrentasvir, Hepatitis C, Chronic
Date of authorisation: 26/07/2017, , Revision: 16, Authorised, Last updated: 20/06/2022
List item

Human medicine European public assessment report (EPAR): Carvykti

ciltacabtagene autoleucel, Multiple Myeloma
Date of authorisation: 25/05/2022, , , , Authorised, Last updated: 17/06/2022
List item

Human medicine European public assessment report (EPAR): Ondexxya

andexanet alfa, Drug-Related Side Effects and Adverse Reactions
Date of authorisation: 26/04/2019, , , Revision: 12, Authorised, Last updated: 17/06/2022
List item

Human medicine European public assessment report (EPAR): Kisplyx

lenvatinib mesilate, Carcinoma, Renal Cell
Date of authorisation: 25/08/2016, , Revision: 17, Authorised, Last updated: 17/06/2022
List item

Human medicine European public assessment report (EPAR): Evrysdi

Risdiplam, Muscular Atrophy, Spinal
Date of authorisation: 26/03/2021, , , Revision: 2, Authorised, Last updated: 17/06/2022
List item

Human medicine European public assessment report (EPAR): Ninlaro

ixazomib citrate, Multiple Myeloma
Date of authorisation: 21/11/2016, , , , Revision: 14, Authorised, Last updated: 17/06/2022
List item

Human medicine European public assessment report (EPAR): Kyprolis

carfilzomib, Multiple Myeloma
Date of authorisation: 19/11/2015, , , Revision: 20, Authorised, Last updated: 15/06/2022
List item

Human medicine European public assessment report (EPAR): Pemazyre

pemigatinib, Cholangiocarcinoma
Date of authorisation: 26/03/2021, , , , Revision: 3, Authorised, Last updated: 15/06/2022
List item

Human medicine European public assessment report (EPAR): Vidaza

azacitidine, Myelodysplastic Syndromes
Date of authorisation: 17/12/2008, , Revision: 25, Authorised, Last updated: 14/06/2022
List item

Human medicine European public assessment report (EPAR): Minjuvi

Tafasitamab, Lymphoma, Large B-Cell, Diffuse
Date of authorisation: 26/08/2021, , , , Revision: 3, Authorised, Last updated: 13/06/2022
List item

Human medicine European public assessment report (EPAR): Jemperli

dostarlimab, Endometrial Neoplasms
Date of authorisation: 21/04/2021, , , Revision: 3, Authorised, Last updated: 10/06/2022
List item

Human medicine European public assessment report (EPAR): Palynziq

Pegvaliase, Phenylketonurias
Date of authorisation: 03/05/2019, , , Revision: 6, Authorised, Last updated: 10/06/2022
List item

Human medicine European public assessment report (EPAR): Gavreto

pralsetinib, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 18/11/2021, , , Revision: 3, Authorised, Last updated: 10/06/2022
List item

Human medicine European public assessment report (EPAR): Cabometyx

cabozantinib (s)-malate, Carcinoma, Renal Cell; Carcinomas, Hepatocellular
Date of authorisation: 09/09/2016, , Revision: 14, Authorised, Last updated: 09/06/2022
List item

Human medicine European public assessment report (EPAR): Polivy

polatuzumab vedotin, Lymphoma, B-Cell
Date of authorisation: 16/01/2020, , , , Revision: 4, Authorised, Last updated: 08/06/2022
List item

Human medicine European public assessment report (EPAR): Deltyba

Delamanid, Tuberculosis, Multidrug-Resistant
Date of authorisation: 27/04/2014,
Date of refusal: 25/07/2013, , , , Revision: 20, Authorised, Last updated: 07/06/2022
List item

Human medicine European public assessment report (EPAR): Symkevi

tezacaftor, ivacaftor, Cystic Fibrosis
Date of authorisation: 31/10/2018, , , Revision: 10, Authorised, Last updated: 07/06/2022
List item

Human medicine European public assessment report (EPAR): Bylvay

Odevixibat, Cholestasis, Intrahepatic
Date of authorisation: 16/07/2021, , , , Revision: 1, Authorised, Last updated: 31/05/2022
List item

Human medicine European public assessment report (EPAR): Rubraca

rucaparib camsylate, Ovarian Neoplasms
Date of authorisation: 23/05/2018, , , , Revision: 8, Authorised, Last updated: 23/05/2022
List item

Human medicine European public assessment report (EPAR): Xospata

gilteritinib fumarate, Leukemia, Myeloid, Acute
Date of authorisation: 24/10/2019, , , Revision: 3, Authorised, Last updated: 20/05/2022
List item

Human medicine European public assessment report (EPAR): Kymriah

tisagenlecleucel, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Large B-Cell, Diffuse
Date of authorisation: 22/08/2018, , , Revision: 11, Authorised, Last updated: 19/05/2022
List item

Human medicine European public assessment report (EPAR): Ayvakyt

avapritinib, Gastrointestinal Stromal Tumors
Date of authorisation: 24/09/2020, , , Revision: 4, Authorised, Last updated: 18/05/2022
List item

Human medicine European public assessment report (EPAR): Tobi Podhaler

Tobramycin, Cystic Fibrosis; Respiratory Tract Infections
Date of authorisation: 20/07/2011, , Revision: 19, Authorised, Last updated: 13/05/2022
List item

Human medicine European public assessment report (EPAR): Zytiga

abiraterone acetate, Prostatic Neoplasms
Date of authorisation: 05/09/2011, , Revision: 24, Authorised, Last updated: 13/05/2022